Owing to complexity of the algorithms and tools very few attempts have been seen for usage of simulation methods in the development of new electrolytes. Moreover, the existing simulation methods focus on only one aspect of the electrolyte at a time and this limits accuracy of simulation results, and affects performance of electrolyte in real world, where multiple factors come into play simultaneously. The method disclosed provides method and system for in-silico optimization and design of electrolytes, enabling prediction of various properties of an electrolytic mixture of salts, solvents and various additives and its suitability for a given battery technology. The in-silico method shapes itself into an overall battery electrolyte property or component composition analyzer based on the user input.

Owing to complexity of the algorithms and tools very few attempts have been seen for usage of simulation methods in the development of new electrolytes. Moreover, the existing simulation methods focus on only one aspect of the electrolyte at a time and this limits accuracy of simulation results, and affects performance of electrolyte in real world, where multiple factors come into play simultaneously. The method disclosed provides method and system for in-silico optimization and design of electrolytes, enabling prediction of various properties of an electrolytic mixture of salts, solvents and various additives and its suitability for a given battery technology. The in-silico method shapes itself into an overall battery electrolyte property or component composition analyzer based on the user input.

The present invention concerns methods to identify RIPK1 modulators capable of modulating RIPK1 activity, RIPK1 interacting molecules that modulate RIPK1 activity and pharmaceutical compositions comprising RIPK1 modulators.

The present invention concerns methods to identify RIPK1 modulators capable of modulating RIPK1 activity, RIPK1 interacting molecules that modulate RIPK1 activity and pharmaceutical compositions comprising RIPK1 modulators.

In order to facilitate product development, such as pharmaceutical product development, a computer implemented method and an apparatus are proposed that enable formulators to develop robust drug formulations in a cost- and time-efficient manner. To start the development process, the user selects the preferred dosage form (e.g., granules, pellets, capsules, tablets etc.), defines a target profile (e.g., amount of active ingredient per unit, size of dosage form, mechanical strength of dosage form, desired release behaviour etc.) and enters key characteristics of the active ingredient (e.g., true density, particle size distribution data, bulk and tapped density, angle of repose, compressibility and compactibility profile etc.). The identity (e.g., chemical name or structure) of the active ingredient is not necessarily disclosed. The apparatus processes the provided data and calculates key parameters of the AI (e.g., particle size, powder density, powder flow and tabletability) Similar key parameters are calculated for common pharmaceutical excipients and stored in the apparatus. The apparatus then selects all relevant excipients and suggests a suitable manufacturing process. Combinations of active ingredients and excipients qualify as drug formulation if the predicted properties comply with the defined target profile. The following aspects can be considered: solubility and permeability of the active ingredient, dissolution of the active ingredient, probability to pass the content uniformity criteria, flowability of the powder blend, tabletability of the powder blend, mechanical strength and size of the tablet, compatibility of active ingredients and excipients etc.

In order to facilitate product development, such as pharmaceutical product development, a computer implemented method and an apparatus are proposed that enable formulators to develop robust drug formulations in a cost- and time-efficient manner. To start the development process, the user selects the preferred dosage form (e.g., granules, pellets, capsules, tablets etc.), defines a target profile (e.g., amount of active ingredient per unit, size of dosage form, mechanical strength of dosage form, desired release behaviour etc.) and enters key characteristics of the active ingredient (e.g., true density, particle size distribution data, bulk and tapped density, angle of repose, compressibility and compactibility profile etc.). The identity (e.g., chemical name or structure) of the active ingredient is not necessarily disclosed. The apparatus processes the provided data and calculates key parameters of the AI (e.g., particle size, powder density, powder flow and tabletability) Similar key parameters are calculated for common pharmaceutical excipients and stored in the apparatus. The apparatus then selects all relevant excipients and suggests a suitable manufacturing process. Combinations of active ingredients and excipients qualify as drug formulation if the predicted properties comply with the defined target profile. The following aspects can be considered: solubility and permeability of the active ingredient, dissolution of the active ingredient, probability to pass the content uniformity criteria, flowability of the powder blend, tabletability of the powder blend, mechanical strength and size of the tablet, compatibility of active ingredients and excipients etc.

A computer-implemented method of identifying a tool compound is provided. The method comprises: searching a database for first candidate compounds that each target one or more first target genes; generating a first fingerprint for each first candidate compound by: searching the database for genes associated with the first candidate compound, and predicting genes associated with the first candidate compound; and filtering the first candidate compounds using the first fingerprints to identify a first optimum compound for targeting the one or more first target genes.

A computer-implemented method of identifying a tool compound is provided. The method comprises: searching a database for first candidate compounds that each target one or more first target genes; generating a first fingerprint for each first candidate compound by: searching the database for genes associated with the first candidate compound, and predicting genes associated with the first candidate compound; and filtering the first candidate compounds using the first fingerprints to identify a first optimum compound for targeting the one or more first target genes.

A system and method for optimizing the latent space in generative machine learning models, and applications of the optimizations for use in the de novo generation of molecules for both ligand-based and pocket-based generation. The ligand-based optimizations comprise a tunable reward system based on a multi-property model and further define new measurable metrics: molecular novelty and uniqueness. The pocket-based optimizations comprise an initial multi-property optimization followed up by either a seed-based optimization or a relaxed-based optimization.

An initial conformation generation apparatus includes one or more memories; and one or more processors coupled to the one or more memories and the one or more processors configured to generate a model representing a cyclic peptide molecule by identifying Cα atoms of each of a plurality of amino acid residues, by arranging the identified Cα atoms on a circumference, and by adding main chains and side chains of the plurality of amino acid residues, and search for a stable conformation of the cyclic peptide molecule by using the generated model as an initial conformation of the cyclic peptide molecule.